Are there any human studies on Declozindol?

No. PubMed returns zero peer-reviewed results for the name, and there is no trusted sourcing. The compound is listed for reference only, and every claim is preclinical or theoretical.

How does it differ from modafinil?

Modafinil is primarily a dopamine transporter (DAT) inhibitor, whereas Declozindol is described mainly as a norepinephrine transporter (NET) inhibitor with orexin-2 modulation. Modafinil is an FDA-approved drug with robust data; Declozindol is an obscure research compound with none.

Safety is unknown. There is no human toxicology or long-term data; NET inhibition theoretically raises heart rate and blood pressure. It is a not-for-human-consumption material.

EmergingResearch compoundReference only

Declozindol

Name: Declozindol
Creator: MolekulaX

Obscure experimental wakefulness research compound, a dechlorinated mazindol analogue. Primarily a selective NET reuptake inhibitor; essentially no human data.

NootropicPerformance BoosterEugeroicStimulantWakefulnessNorepinephrineDopamineAnti-fatigue

Pharmacology

ClassEugeroic · Stimulant · Wakefulness

Primary targetNorepinephrine transporter (NET), reuptake inhibition

Targets3 receptor targets

Half-lifeN/A

OnsetN/A

EvidenceReference only

Affected systemsNorepinephrineDopamineAnti-fatigue

Contents

WHAT IS DECLOZINDOL?

Detailed overview

Declozindol is an obscure, experimental wakefulness-promoting (eugeroic) research compound described as a dechlorinated (chlorine-free) analogue of mazindol. Its proposed mechanism is selective reuptake inhibition at the norepinephrine transporter (NET), complemented by moderate modulation of the orexin-2 receptor (OX2) and weak dopamine transporter (DAT) affinity. There are no peer-reviewed human or animal studies and no trusted sourcing for this compound, so it is included for reference only. All information here is preliminary and should not be treated as evidence of safety or efficacy.

Mechanism

Selective NET reuptake inhibitor

Key target

Norepinephrine transporter (NET)

Evidence level

Reference-only (no human data)

Legal status

Unapproved research compound

Chemical formula

N/A (not reported)

Receptor profile

Norepinephrine transporter (NET)Strong
Orexin-2 receptor (OX2)Moderate
Dopamine transporter (DAT)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 4

Raised heart rate and blood pressure (sympathomimetic effect of NET inhibition)
Insomnia, disturbed sleep (wakefulness-promoting profile)
Appetite suppression
Unknown long-term safety profile (no human data)

Contraindications · 5

No approved clinical use: strictly an experimental research compound with no human safety data
Cardiovascular disease (hypertension, arrhythmia): NET inhibition may raise heart rate and blood pressure
Anxiety disorders, insomnia: the wakefulness-promoting effect may worsen them
Pregnancy and breastfeeding: no reproductive safety data
With MAO inhibitors or other noradrenergic agents: additive sympathomimetic risk

Related Nootropics

Same therapeutic category

FAQ

Obscure experimental wakefulness research compound, a dechlorinated mazindol analogue. Primarily a selective NET reuptake inhibitor; essentially no human data.

Have a question about Declozindol?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic

UpdatedJuly 9, 2026

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA

Updated: July 9, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.